R
RGNX
Regenxbio
6.69
+0.38+6.02%After Hours: 6.53 -0.16 -2.39%17:39 05/27 EDT
OPEN/PREV CLOSE6.35/6.31
TODAY RANGE6.35-6.76
VOL1.53M
MARKET CAP345.86M
52 WEEK RANGE5.46-16.19
AVG VOL (3M)1.19M
% TURNOVER2.97%
TURNOVER--
P/E (TTM)-1.1968
% RANGE6.42%
EPS(TTM)-5.5900
P/E(FORWARD)-2.0712
P/B16.38
BVPS0.4084
DIVIDEND--
P/S1.998
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP314.73M
SHARES OUTSTANDING51.70M
NEXT EARNINGS08/05-08/10
FREE FLOAT47.04M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
TipRanks·11h ago
Stifel Nicolaus Sticks to Their Buy Rating for RegenXBio (RGNX)
TipRanks·05/20 05:24
RegenXbio’s RGX-202 Pivotal Win Lifts Outlook
TipRanks·05/19 00:02
RegenXBio’s Earnings Call Signals Pivotal Gene-Therapy Win
PUBT·05/18 20:06
Regenxbio joins RBC Global Healthcare Conference fireside chat
PR Newswire·05/18 20:05
REGENXBIO to Participate in Upcoming Investor Conferences
Seeking Alpha·05/16 12:30
Regenxbio: 'Hold' On RGX-121 CRL MPS II And RGX-202 DMD Results
Dow Jones·05/15 18:05
REGENXBIO Price Target Cut to $14.00/Share From $25.00 by B of A Securities
Dow Jones·05/15 18:05
REGENXBIO Is Maintained at Buy by B of A Securities
Benzinga·05/15 17:55
B of A Securities Maintains Buy on Regenxbio, Lowers Price Target to $14
TipRanks·05/15 15:28
RegenXBio (RGNX) Gets a Buy from Leerink Partners
Dow Jones·05/15 14:19
REGENXBIO Price Target Cut to $12.00/Share From $37.00 by Barclays
Dow Jones·05/15 14:19
REGENXBIO Is Maintained at Overweight by Barclays
Benzinga·05/15 14:09
Barclays Maintains Overweight on Regenxbio, Lowers Price Target to $12